

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA – Dinutuximab beta for treating neuroblastoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

During the scoping stage one commentator stated that dinutuximab beta is a very high cost drug, and that failure to achieve a positive NICE recommendation would result in inequitable access to this therapy for children within the UK. The preliminary view during the scoping stage was that this issue was not an equality issue for several reasons, and it was therefore not discussed by the committee.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No potential equality issues have been raised in the submissions, expert statements or academic report.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No potential equality issues have been identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Not applicable.

**Approved by Associate Director (name):** Helen Knight

**Date:** 25/04/2018

**Final appraisal determination**

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

The company suggested that the evaluation framework of the single technology appraisal process discriminated against children with rare diseases.

The committee did not consider this to be an equality issue. When formulating its recommendations the appraisal committee has discretion to consider those factors it believes are most appropriate to each appraisal and in doing so has regard to NICE's legal obligations on human rights, discrimination and equality.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Not applicable.

**Approved by Associate Director (name):** Helen Knight

**Date:** 05/07/2018